This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/526873-ema-no-covid-vaccine-efficacy-threshold/
The article has changed 3 times. There is an RSS feed of changes available.
| Version 0 | Version 1 |
|---|---|
| EU drugs regulator says it won’t impose 50% efficacy threshold for Covid-19 vaccines after disappointing result in CureVac trial | EU drugs regulator says it won’t impose 50% efficacy threshold for Covid-19 vaccines after disappointing result in CureVac trial |
| (2 months later) | |
| The European Medicines Agency (EMA) has said it will not bring in a minimum efficacy threshold for Covid-19 vaccines. The comment comes after clinical trials showed Germany’s CureVac jab to be only 47% effective against the virus. | The European Medicines Agency (EMA) has said it will not bring in a minimum efficacy threshold for Covid-19 vaccines. The comment comes after clinical trials showed Germany’s CureVac jab to be only 47% effective against the virus. |
| CureVac announced data on the efficacy of its jab on Wednesday after it was tested in second- and third-phase trials involving 40,000 people across ten countries. | CureVac announced data on the efficacy of its jab on Wednesday after it was tested in second- and third-phase trials involving 40,000 people across ten countries. |
| The company suggested variants of the virus may be behind the poor result. | The company suggested variants of the virus may be behind the poor result. |
| On Thursday, the EMA’s vaccine chief Marco Cavaleri said it was “a bit early to say” after being asked by a journalist about the CureVac results and the threat variants may pose to vaccine efficacy. | On Thursday, the EMA’s vaccine chief Marco Cavaleri said it was “a bit early to say” after being asked by a journalist about the CureVac results and the threat variants may pose to vaccine efficacy. |
| “We will need to collect all the final data from this clinical trial, and have a good analysis of the outcome throughout different regions, age groups and according to different variants,” he told an EMA briefing. | “We will need to collect all the final data from this clinical trial, and have a good analysis of the outcome throughout different regions, age groups and according to different variants,” he told an EMA briefing. |
| Asked specifically about a 50% efficacy minimum level for vaccines, he added that the EMA had “always felt it was difficult to define upfront a threshold.” | Asked specifically about a 50% efficacy minimum level for vaccines, he added that the EMA had “always felt it was difficult to define upfront a threshold.” |
| Think your friends would be interested? Share this story! | Think your friends would be interested? Share this story! |
| Dear readers and commenters, | |
| We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system. | |
| Sorry for the inconvenience, and looking forward to your future comments, | |
| RT Team. |